IDX184

• CAT Number: I007266
• CAS Number: 1036915-08-8
• Molecular Formula: C25H35N6O9PS
• Molecular Weight: 626.62
• Purity: ≥95%
• Synonyms: S-[2-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl]oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate
• InChI: InChI=1S/C25H35N6O9PS/c1-24(2,13-32)22(35)42-10-9-38-41(37,28-11-15-7-5-4-6-8-15)39-12-16-18(33)25(3,36)21(40-16)31-14-27-17-19(31)29-23(26)30-20(17)34/h4-8,14,16,18,21,32-33,36H,9-13H2,1-3H3,(H,28,37)(H3,26,29,30,34)/t16-,18-,21-,25-,41?/m1/s1
• InChIKey: FGHMGRXAHIXTBM-TWFJNEQDSA-N
• SMILES: C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(NCC4=CC=CC=C4)OCCSC(=O)C(C)(C)CO)O)O

IDX184（Cat No.:I007266）is a potent liver-targeted prodrug of 2′-C-methylguanosine, designed as a nucleotide analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (NS5B). Once metabolized in hepatocytes, it generates the active triphosphate form that competes with natural nucleotides, blocking viral RNA synthesis and replication. IDX184 showed promising antiviral activity with improved liver selectivity and reduced systemic exposure, aiming to minimize toxicity. Although clinical development was discontinued, IDX184 remains important in antiviral research as a reference compound for exploring nucleoside-based therapies against HCV and related viral infections.